Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00952744 · ClinicalTrials.gov registry record
Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction
A clinical trial of Acute Coronary Syndromes, sponsored by Brahms.
- Completed
- Registry status
- 2,071
- Enrollment target
- 11
- Study locations
NCT00952744 is a study of Acute Coronary Syndromes that has completed, run by Brahms. The registered enrollment target is 2,071 participants, above the 146-participant average among 3 other Acute Coronary Syndromes trials with a reported enrollment target (1318% higher). The trial reports 11 study locations across 9 states.
The verdict
NCT00952744, a study of Acute Coronary Syndromes, has completed, sponsored by Brahms.
- COMPLETED
- Registry status
- 2,071 participants
- Enrollment target
- 11
- Study locations
Study Summary
While troponin is not detectable until several hours after an Acute Myocardial Infarction (AMI), copeptin is expected to be elevated very early after an AMI. A combination of both markers for the diagnosis of AMI early after the event is therefore expected to be advantageous.
Conditions Studied
Study Locations (11)
California
- Stanford University Hospital - Palo Alto
- University of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
Kansas
- Kansas University Medical Center - Kansas City
Maryland
- University of Maryland - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Henry Ford Hospital - Detroit
Minnesota
- Hennepin County Medical Center - Minneapolis
Ohio
- The Cleveland Clinic - Cleveland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,071 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00952744
The ClinicalTrials.gov registry entry for NCT00952744 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,071 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 146-participant average among 3 other Acute Coronary Syndromes trials with a reported enrollment target (1318% higher). The listed sponsor is Brahms, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Coronary Syndromes appearing as the primary indexed condition, and to 0 interventions.
NCT00952744 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Kansas, Maryland.
Frequently Asked Questions
What is clinical trial NCT00952744 about?
NCT00952744 is a clinical study titled "Investigation of the Biomarker Copeptin in Patients With Acute Myocardial Infarction". While troponin is not detectable until several hours after an Acute Myocardial Infarction (AMI), copeptin is expected to be elevated very early after an AMI. A combination of both markers for the diagnosis of AMI early after the event is therefore expected to be advantageous.
What is the current status of trial NCT00952744?
This trial is currently completed. The enrollment target is 2,071 participants. The study started on 2009-08. Estimated completion is 2011-10.
What conditions does trial NCT00952744 study?
This clinical trial studies the following conditions: Acute Coronary Syndromes.
Who is sponsoring clinical trial NCT00952744?
This trial is sponsored by Brahms, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00952744 being conducted?
This trial has 11 study locations across California, Kansas, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Coronary Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.